



Published in final edited form as:

*Hypertension*. 2012 November ; 60(5): 1213–1219. doi:10.1161/HYPERTENSIONAHA.112.198820.

## An Elevation in Physical Coupling of Type 1 IP<sub>3</sub> Receptors to TRPC3 Channels Constricts Mesenteric Arteries in Genetic Hypertension

Adebowale Adebisi, Candice M. Thomas-Gatewood, M. Dennis Leo, Michael W. Kidd, Zachary P. Neeb, and Jonathan H. Jaggar\*

Department of Physiology, University of Tennessee Health Science Center, Memphis TN 38163

### Abstract

Hypertension is associated with an elevation in agonist-induced vasoconstriction, but mechanisms involved require further investigation. Many vasoconstrictors bind to phospholipase C-coupled receptors, leading to an elevation in inositol 1,4,5-trisphosphate (IP<sub>3</sub>) that activates sarcoplasmic reticulum (SR) IP<sub>3</sub> receptors (IP<sub>3</sub>Rs). In cerebral artery myocytes, IP<sub>3</sub>Rs release SR Ca<sup>2+</sup> and can physically couple to canonical transient receptor potential 3 (TRPC3) channels in a caveolin-1-containing macromolecular complex, leading to cation current (I<sub>CaT</sub>) activation that stimulates vasoconstriction. Here, we investigated mechanisms by which IP<sub>3</sub>Rs control vascular contractility in systemic arteries and IP<sub>3</sub>R involvement in elevated agonist-induced vasoconstriction during hypertension. Total and plasma membrane-localized TRPC3 protein was ~2.7- and 2-fold higher in mesenteric arteries of hypertensive spontaneously hypertensive rats (SHR) than in Wistar-Kyoto (WKY) rat controls, respectively. In contrast, IP<sub>3</sub>R1, TRPC1, TRPC6, and caveolin-1 expression was similar. TRPC3 expression was also similar in arteries of pre-hypertensive SHR and WKY rats. Control, IP<sub>3</sub>- and endothelin-1 (ET-1)-induced FRET between IP<sub>3</sub>R1 and TRPC3 was higher in hypertensive SHR than WKY myocytes. IP<sub>3</sub>-induced I<sub>CaT</sub> was ~3-fold larger in SHR myocytes. Pyr3, a selective TRPC3 channel blocker, and CIRBP-TAT, an IP<sub>3</sub>R-TRP physical coupling inhibitor, reduced IP<sub>3</sub>-induced I<sub>CaT</sub> and ET-1-induced vasoconstriction more in SHR than WKY myocytes and arteries. Thapsigargin, a SR Ca<sup>2+</sup>-ATPase blocker, did not alter ET-1-stimulated vasoconstriction in SHR or WKY arteries. These data indicate that ET-1 stimulates physical coupling of IP<sub>3</sub>R1 to TRPC3 channels in mesenteric artery myocytes, leading to vasoconstriction. Furthermore, an elevation in IP<sub>3</sub>R1 to TRPC3 channel molecular coupling augments ET-1-induced vasoconstriction during hypertension.

### Keywords

Hypertension; vasoconstriction; TRPC channels; IP<sub>3</sub> receptors; endothelin-1

\*To whom correspondence should be addressed: Telephone: 901-448-1208, Fax: 901-448-7126, jjaggar@uthsc.edu.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

### Conflicts of Interest/Disclosures

None.

## Introduction

Hypertension is associated with arterial hypercontractility that alters vascular bed hemodynamics (1;2). Several mechanisms have been proposed to stimulate vasoconstriction in hypertension, including altered myocyte ion channel expression and function (3). An increase in myocyte voltage-dependent  $\text{Ca}^{2+}$  current density elevates intracellular  $\text{Ca}^{2+}$  concentration ( $[\text{Ca}^{2+}]_i$ ), leading to vasoconstriction in hypertension (4;5). In hypertensive animal models, a reduction in expression and function of the  $\beta_1$  subunit of the large conductance  $\text{Ca}^{2+}$ -activated  $\text{K}^+$  ( $\text{BK}_{\text{Ca}}$ ) channel increases vascular tone (6;7). Altered expression of several transient receptor potential (TRP) channels is also proposed to be associated with systemic and pulmonary hypertension (8). However, molecular mechanisms by which alterations in TRP channel expression result in vasoconstriction in hypertension are poorly understood.

Many vasoconstrictors bind to phospholipase C-coupled receptors, leading to an elevation in inositol 1,4,5-trisphosphate ( $\text{IP}_3$ ) that activates endo/sarcoplasmic reticulum-localized  $\text{IP}_3$  receptors ( $\text{IP}_3\text{Rs}$ ) (9). Three structurally and functionally distinct  $\text{IP}_3\text{R}$  isoforms, designated  $\text{IP}_3\text{R1}$ ,  $\text{IP}_3\text{R2}$ , and  $\text{IP}_3\text{R3}$  have been identified (10).  $\text{IP}_3\text{R1}$  is the predominant molecular and functional isoform expressed in vascular myocytes (10). Agonist-induced  $\text{IP}_3\text{R}$  activation results in sarcoplasmic reticulum (SR)  $\text{Ca}^{2+}$  release in cerebral artery myocytes that partially contributes to constriction (10). Close spatial proximity of  $\text{IP}_3\text{R1}$  to plasma membrane canonical transient receptor potential 3 (TRPC3) channels also permits  $\text{IP}_3$  to promote binding of the  $\text{IP}_3\text{R1}$  N-terminus to the TRPC3 channel calmodulin and  $\text{IP}_3\text{R}$  binding (CIRB) domain (11). Isoform-selective physical coupling of  $\text{IP}_3\text{R1}$  to TRPC3 channels activates a cation current ( $I_{\text{Cat}}$ ) in cerebral artery myocytes (11;12).  $\text{IP}_3$ -induced  $I_{\text{Cat}}$  activation leads to membrane depolarization, voltage-dependent  $\text{Ca}^{2+}$  channel activation, an elevation in global  $[\text{Ca}^{2+}]_i$  and vasoconstriction (13). This physical coupling mechanism is essential for  $\text{IP}_3$ -induced  $I_{\text{Cat}}$  activation and a major contributor to agonist-induced constriction in cerebral arteries (11;12;14). In contrast, mechanisms by which  $\text{IP}_3\text{Rs}$  control systemic artery contractility are poorly understood, with contributions of SR  $\text{Ca}^{2+}$  release and physical coupling of  $\text{IP}_3\text{Rs}$  to TRP channels unclear. Similarly, whether pathological alterations in  $\text{IP}_3\text{R}$ -mediated signaling contribute to elevated systemic vascular contractility during hypertension is poorly understood.

Here, we investigated physiological functions of  $\text{IP}_3\text{Rs}$  in myocytes of mesenteric arteries. We also tested the associated hypothesis that molecular and functional alterations in  $\text{IP}_3\text{R}$  signaling contribute to mesenteric artery vasoconstriction in hypertension. Our data indicate that  $\text{IP}_3$  and endothelin-1 (ET-1) stimulate physical coupling of  $\text{IP}_3\text{R1}$  to TRPC3 channels, leading to  $I_{\text{Cat}}$  activation in mesenteric artery myocytes and vasoconstriction. Data also indicate that hypertension is associated with an elevation in  $\text{IP}_3$ -induced physical coupling of  $\text{IP}_3\text{R1}$  to TRPC3 channels, leading to vasoconstriction. In contrast, ET-1 does not induce vasoconstriction by stimulating SR  $\text{Ca}^{2+}$  release in arteries of normotensive or hypertensive rats. In summary, our findings indicate that an elevation in  $\text{IP}_3\text{R1}$  to TRPC3 channel molecular coupling contributes to vasoconstriction during hypertension.

## Materials and Methods

Expanded Materials and Methods are available as Supplemental Documentation.

## Results

### IP<sub>3</sub>R1 interacts with TRPC3 and cav-1 in mesenteric arteries

IP<sub>3</sub>R1, TRPC3 and cav-1 are located in the same macromolecular complex and physically interact in cerebral artery myocytes (12). Whether these proteins structurally organize in systemic arteries is unclear. Co-IP was used to examine whether IP<sub>3</sub>R1 associates with TRPC3 channels and cav-1 in Wistar-Kyoto (WKY) rat mesenteric arteries. A monoclonal mouse anti-IP<sub>3</sub>R1 antibody co-immunoprecipitated IP<sub>3</sub>R1, TRPC3, and cav-1 from WKY rat mesenteric artery lysate (Fig. 1). These data suggest that IP<sub>3</sub>R1, TRPC3 channels and cav-1 exist in the same macromolecular complex in mesenteric arteries.

### Hypertension is associated with an elevation in TRPC3, but not TRPC1, TRPC6, IP<sub>3</sub>R1 or cav-1, protein in mesenteric arteries

At 6 weeks of age, WKY and Spontaneously Hypertensive (SHR) rat blood pressures (tail cuff systolic, WKY vs. SHR: ~ 137 vs. 137 mmHg) are similar (15). In contrast, at 12 weeks of age, WKY and SHR blood pressures (~151 vs. 217 mmHg, respectively) are significantly different (15). Western blotting indicated that TRPC3 protein was ~2.7-fold higher in hypertensive (13 wk) SHR than in age-matched WKY rat mesenteric arteries (Fig. 2A,G; Data Supplement Fig. S1). In contrast, TRPC1, TRPC6, IP<sub>3</sub>R1 and cav-1 proteins were similar (Fig. 2B–E,G). To examine the hypothesis that hypertension is a factor associated with elevated vascular TRPC3 expression, protein was compared in 6 week old pre-hypertensive SHR and WKY rat arteries. TRPC3 protein was similar in 6 week old SHR and WKY rat mesenteric arteries (Fig. 2F,G, Data Supplement Fig. S1). These data indicate that TRPC3 protein increases during the development of genetic hypertension, whereas TRPC1, TRPC6, IP<sub>3</sub>R1 and cav-1 expression remain unaltered in mesenteric arteries.

### Plasma membrane-localized TRPC3 channel protein is elevated in SHR arteries

Arterial surface biotinylation was performed to examine cellular distribution of TRPC3 channels in mesenteric arteries. Biotinylation indicated that ~ 99.6 and 98.8 % of total TRPC3 protein was present in the arterial plasma membrane in SHR and WKY rats, respectively (Fig. 3A,B). Surface TRPC3 protein was ~2-fold higher in SHR than WKY arteries (Fig. 3A,C). These data indicate that TRPC3 channels are predominantly membrane-localized in mesenteric arteries. Furthermore, during hypertension the increase in TRPC3 channel expression directly translates to an elevation in plasma membrane TRPC3 protein.

### Hypertension is associated with increased spatial localization of TRPC3 channels nearby IP<sub>3</sub>R1 in arterial myocytes

Next, we investigated spatial proximity between arterial myocyte IP<sub>3</sub>R1 and TRPC3 in SHR and WKY mesenteric artery myocytes. Alexa 546- and 488-labeled secondary antibodies bound to primary antibodies targeting IP<sub>3</sub>R1 and TRPC3, respectively, produced mean N-FRET of ~23.7% in isolated WKY rat arterial myocytes (Fig. 4A,B). In SHR myocytes, the same antibodies produced a higher mean N-FRET of ~29.1% (Figure 4A,B). Bt-IP<sub>3</sub>, a membrane-permeant IP<sub>3</sub> analogue, and ET-1, a vasoconstrictor, both increased mean N-FRET to ~28% in WKY myocytes (Fig. 4B). Bt-IP<sub>3</sub> and ET-1 stimulated a larger increase in mean N-FRET to ~34 and 35 %, respectively in SHR myocytes (Fig. 4B). To test the hypothesis that hypertension is associated with an elevation in spatial localization of IP<sub>3</sub>R1 and TRPC3 channels in arterial myocytes, N-FRET was measured in mesenteric artery myocytes from 6 week old pre-hypertensive SHR and WKY rats. Baseline and the ET-1-stimulated elevation in mean N-FRET were similar in 6 week old SHR and WKY myocytes (Fig. 4C). These data indicate that TRPC3 is located in close spatial proximity to IP<sub>3</sub>R1, that IP<sub>3</sub> and ET-1 increase molecular localization between these proteins, and that hypertension

is associated with an elevation in the spatial localization of TRPC3 channels to IP<sub>3</sub>R1 in mesenteric artery myocytes.

### **IP<sub>3</sub> stimulates larger cation currents (I<sub>Cat</sub>) in SHR than WKY myocytes**

The significance of an elevation in TRPC3 channel expression and IP<sub>3</sub>R1 to TRPC3 molecular localization in SHR arterial myocytes was investigated by measuring I<sub>Cat</sub> using patch-clamp electrophysiology. Control I<sub>Cat</sub> density was similar in SHR and WKY arterial myocytes with mean values at ~6 pA/pF at -120 mV (Fig 5A,B). IP<sub>3</sub> increased mean I<sub>Cat</sub> density by ~ 6 pA/pF in WKY myocytes and by ~ 18 pA/pF in SHR myocytes, or ~ 3-fold more (at -120 mV, Fig. 6A,B). Pyr3, a selective TRPC3 channel blocker (16), reduced IP<sub>3</sub>-induced I<sub>Cat</sub> in SHR and WKY rat arterial myocytes by ~ 90 and 76 %, respectively (Fig. 5A,B). CIRBP-TAT, a membrane-permeant peptide that blocks physical coupling of IP<sub>3</sub>Rs to TRPC channels (11;17), inhibited IP<sub>3</sub>-induced I<sub>Cat</sub> in SHR and WKY rat myocytes similarly to Pyr3 (Fig. 5A,B). These data indicate that IP<sub>3</sub> stimulates physical coupling of IP<sub>3</sub>R1 to TRPC3 channels, leading to I<sub>Cat</sub> activation in mesenteric artery myocytes. Data also reveal that augmentation of this coupling mechanism elevates IP<sub>3</sub>-induced TRPC3 currents in SHR myocytes during hypertension.

### **ET-1 stimulates larger vasoconstriction through an SR Ca<sup>2+</sup> release-independent mechanism in SHR mesenteric arteries**

The contribution of IP<sub>3</sub>Rs and TRPC channel activation to ET-1-induced mesenteric artery constriction was examined. ET-1 stimulated concentration (1–100 nM)-dependent vasoconstriction in both WKY and SHR arteries. ET-1-induced vasoconstriction was larger at all concentrations studied, as was maximal force generation, in SHR arteries (Fig. 6A). In contrast, the half-maximal effective concentration (*EC*<sub>50</sub>) of ET-1 was similar in SHR (3.05 nM) and WKY (2.40 nM) arteries. Depolarization (80 mM KCl)-induced constriction was also larger in SHR than WKY rat mesenteric arteries ( $\Delta$  tension, SHR vs. WKY:  $6.9 \pm 1.3$  mN vs.,  $3.5 \pm 0.4$ ; n=14 for each; *P*<0.05). Thapsigargin, a SR Ca<sup>2+</sup>-ATPase inhibitor that abolishes sarcoplasmic reticulum Ca<sup>2+</sup> release, did not alter baseline tension or ET-1-induced vasoconstriction in SHR and WKY arteries (Data Supplement Fig. S2, Fig. 6B). These findings indicate that ET-1-induced vasoconstriction occurs independently of SR Ca<sup>2+</sup> release in mesenteric arteries of both SHR and WKY rats and is larger in SHR arteries. Data also suggest that ET-1 sensitivity is similar in SHR and WKY arteries.

### **Pathological vasoconstriction occurs due to an elevation in physical coupling of IP<sub>3</sub>R1 to TRPC3 channels in myocytes**

The functional significance of IP<sub>3</sub>R1 to TRPC3 channel physical coupling in mediating ET-1-induced vasoconstriction was studied. 2-APB, an IP<sub>3</sub>R and TRPC channel inhibitor, did not alter baseline arterial tension or depolarization-induced vasoconstriction (Data Supplement Figs. S2 and S3). In contrast, 2-APB reduced ET-1-induced vasoconstriction, doing so more effectively in SHR than WKY arteries (~34 versus 18 % reduction, respectively; Fig. 6C). Pyr3 and CIRBP-TAT did not alter baseline tension or depolarization-induced vasoconstriction, but both blockers inhibited ET-1-induced vasoconstriction (Data Supplement Figs. S2 and S3, and Figure 6C). Importantly, Pyr3 more effectively blocked ET-1-induced constriction in SHR than WKY arteries (~83 % versus 59 % reduction, respectively; Fig. 6C). CIRBP-TAT also attenuated ET-1-induced constriction more in SHR than WKY arteries (~57 versus 39 % reduction, respectively; Fig. 6C). Taken together, these data indicate that an elevation in plasma membrane TRPC3 channels and physical coupling of these channels to IP<sub>3</sub>R1 in myocytes augments ET-1-induced vasoconstriction during hypertension.

## Discussion

Here, we studied the functional significance of IP<sub>3</sub>Rs and TRPC3 channels to agonist-induced vasoconstriction in mesenteric arteries and the contribution of pathological alterations in IP<sub>3</sub>R-mediated signaling mechanisms during hypertension. Our data show for the first time that IP<sub>3</sub>R1 is located in close proximity to TRPC3 and is contained within a macromolecular complex containing TRPC3 and cav-1 in mesenteric arteries. Hypertension is associated with an increase in both total and plasma-membrane TRPC3 protein and IP<sub>3</sub>R1 to TRPC3 spatial localization, leading to an elevation in IP<sub>3</sub>-induced I<sub>CaT</sub> in arterial myocytes. SR Ca<sup>2+</sup> release does not contribute to ET-1-induced vasoconstriction in mesenteric arteries of either normotensive or hypertensive rats, suggesting that IP<sub>3</sub>R activation stimulates vasoconstriction through alternate mechanisms. Our data indicate that physical coupling of IP<sub>3</sub>R1 to TRPC3 channels contributes to ET-1-induced vasoconstriction in mesenteric arteries and that enhancement of this mechanism contributes to the elevation in ET-1-induced vasoconstriction during hypertension.

TRPC3 expression is altered in several cell types in hypertension. TRPC3 mRNA and protein were elevated in lung tissues and pulmonary artery myocytes from patients with idiopathic pulmonary hypertension (18). When compared with normotensive controls, TRPC3 protein was also higher in SHR and human monocytes, human renal arteriolar endothelium, kidney cortex of hypertensive Munich Wistar Frömter rats and SHR aorta, mesenteric, carotid and cerebral arteries (19–24). Our data indicating that TRPC3 protein is higher in mesenteric arteries of hypertensive SHR than age-matched WKY rats is consistent with these results from other cell types. Mechanisms that elevate arterial myocyte TRPC3 channels in SHR are unclear. Conceivably, the chronic elevation in blood pressure may stimulate transcriptional upregulation of TRPC3 channels. In addition, TRPC3 upregulation may be one mechanism that elevates systemic blood pressure. Functional and molecular alterations in IP<sub>3</sub>R1 and cav-1 also occur during hypertension. Pulmonary hypertension was associated with an elevation in pulmonary artery IP<sub>3</sub>R1 mRNA and protein, whereas IP<sub>3</sub>R1 expression was lower in renal medulla of SHR than WKY rats (25;26). Although cav-1 knockout mice develop pulmonary hypertension, cav-1 protein was lower in SHR than WKY rat aorta (27;28). Data from this and our previous study indicate that IP<sub>3</sub>R1, TRPC3, and cav-1 exist in a macromolecular signaling complex in both cerebral and mesenteric arteries (12). Cav-1 and IP<sub>3</sub>R1 expression were similar in SHR and WKY mesenteric arteries, suggesting that altered cav-1 and IP<sub>3</sub>R1 expression may be tissue-dependent in hypertension. TRPC3, TRPC1, and TRPC6 channels regulate membrane potential, [Ca<sup>2+</sup>]<sub>i</sub> and contractility in myocytes from a wide variety of different blood vessels (29). Lower carotid artery and higher mesenteric arteriole TRPC1 protein has been reported in SHR rats (23;24). TRPC6 protein was also higher in mesenteric artery myocytes of Milan hypertensive rats and ouabain-induced hypertensive rats than in normotensive controls (30;31). Our data indicate that TRPC1 and TRPC6 protein is similar in SHR and WKY rat mesenteric arteries. These *contradictory data may result from differences in the arterial bed and/or animal models of hypertension studied.*

Hypertension is associated with pathological alterations in vascular myocyte contractility, morphology, gene expression, and proliferation (32). These changes *may occur due to altered* trafficking, cell surface expression, and spatial localization of signaling molecules, leading to dysregulation of physiological functions, including contractility. A proportion of TRPC3 protein is located intracellularly in a variety of cell types, including cerebral artery myocytes and cardiomyocytes (11;33). Data here show that essentially 100% of TRPC3 protein is located within the plasma membrane in mesenteric arteries, suggesting that TRPC3 distribution may differ depending on the cell type or anatomical origin of the vasculature. FRET experiments indicated that IP<sub>3</sub>R1 and TRPC3 channels are located in

close spatial proximity and that ET-1 and IP<sub>3</sub> increase spatial proximity of these proteins in mesenteric artery myocytes, consistent with data in cerebral artery myocytes (11;12). IP<sub>3</sub>R1 and TRPC3 antibodies generated a higher FRET signal in SHR myocytes that could originate from an increase in the number of TRPC3 channels nearby IP<sub>3</sub>R1 or from a reduction in the distance between TRPC3 and IP<sub>3</sub>R1, possibilities between which the FRET method cannot distinguish. Given that surface TRPC3 is higher and that IP<sub>3</sub>R1 and TRPC3 are already in such close spatial proximity to permit physical coupling, it is highly likely that the higher FRET signal occurs, at least in part, due to a larger number of TRPC3 channels nearby IP<sub>3</sub>R1.

ET-1 and UTP activate an IP<sub>3</sub>R1-dependent TRPC3-mediated I<sub>CaT</sub> in cerebral artery myocytes (13;14;34). UTP-induced whole cell currents were also larger in SHR carotid artery myocytes, although signaling mechanisms involved were not determined (24). Here, data indicate that IP<sub>3</sub> stimulates physical coupling between IP<sub>3</sub>R1 and TRPC3 channels, leading to I<sub>CaT</sub> in mesenteric artery myocytes. IP<sub>3</sub>-induced I<sub>CaT</sub> density was larger in SHR than WKY rat myocytes, likely due to an increased number of TRPC3 channels nearby IP<sub>3</sub>R1 and an elevation in functional coupling. This conclusion is supported by data indicating that Pyr3 and CIRBP-TAT essentially abolished IP<sub>3</sub>-induced I<sub>CaT</sub> in both WKY and SHR myocytes. These data also indicate that hypertension is not associated with the induction of promiscuous coupling of IP<sub>3</sub>Rs to TRP channels other than C3, a potential mechanism that may have also elevated I<sub>CaT</sub>.

Small arteries from hypertensive humans and rats generate higher spontaneous tone and constrict more in response to receptor agonists (1;2;24;35–39). Here, although ET-1 and membrane depolarization stimulated larger vasoconstriction in SHR arteries, ET-1 sensitivity was similar, consistent with previous studies in perfused mesenteric arteries (40;41). When combined with other findings in this study, these data suggest that ET-1 stimulates larger vasoconstriction, in part, through stimulating more effective IP<sub>3</sub>R1-TRPC3 physical coupling in myocytes of hypertensive rats. This leads to larger I<sub>CaT</sub>, membrane depolarization, voltage-dependent Ca<sup>2+</sup> channel activation, and vasoconstriction. Our data also indicate that SR Ca<sup>2+</sup> release does not contribute to ET-1-induced vasoconstriction in either SHR or WKY mesenteric arteries, supporting the concept that physical coupling to TRPC3 channels is a primary mechanism by which IP<sub>3</sub>Rs stimulate vasoconstriction in mesenteric arteries. Data also show that IP<sub>3</sub>Rs and TRPC3 channels do not contribute to depolarization-induced vasoconstriction and that 2-APB, Pyr3 and CIRBP-TAT do not block voltage-dependent Ca<sup>2+</sup> channels which elicit this response. Many vasoconstrictors, including angiotensin II and epinephrine, bind to phospholipase C-coupled receptors, leading to an elevation in intracellular IP<sub>3</sub> in smooth muscle cells. Therefore, our study also raises the possibility that other agonists may induce vasoconstriction by stimulating IP<sub>3</sub>R1 to TRPC3 coupling and that this mechanism may contribute to elevated contractility during hypertension.

In summary, data indicate that IP<sub>3</sub>R1 stimulates vasoconstriction primarily through physical coupling to TRPC3 channels in mesenteric artery myocytes. We also demonstrate that genetic hypertension is associated with an increase in TRPC3 protein, TRPC3 channel cell surface expression and enhanced physical coupling of TRPC3 to IP<sub>3</sub>R1 channels. This pathological alteration elevates ET-1-induced vasoconstriction in hypertension.

## Perspective

An elevation in vascular resistance is a hallmark of hypertension (1;2). Identifying mechanisms that underlie vasoconstriction in hypertension is essential to develop novel therapies to induce vasodilation. We show that IP<sub>3</sub>R1 physically and functionally couples to

TRPC3 channels in mesenteric artery myocytes, similarly to previous data in cerebral artery myocytes (11). We also identify a novel mechanism by which enhanced molecular and functional coupling of TRPC3 channels to IP<sub>3</sub>R1 elevates arterial contractility in hypertension. An increase in TRPC3 channel protein, TRPC3 channel surface expression, and molecular localization of these channels nearby IP<sub>3</sub>R1 enhances physical and functional coupling of IP<sub>3</sub>R1 to TRPC3 in SHR mesenteric artery myocytes. This pathological alteration in IP<sub>3</sub>R1 to TRPC3 coupling augments agonist and IP<sub>3</sub>-induced I<sub>CaT</sub> in arterial myocytes and vasoconstriction in hypertension. Our study also provides evidence that interfering with physical and functional coupling between IP<sub>3</sub>R1 and TRPC3 channels may be a novel therapeutic strategy to induce vasodilation in hypertension.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

### Sources of Funding

This work was supported by National Institute of Health grants HL67061, HL094378, and HL110347 (J.H.J.) and HL096411 (A.A.).

## References

1. Mayet J, Hughes A. Cardiac and vascular pathophysiology in hypertension. *Heart*. 2003; 89:1104–1109. [PubMed: 12923045]
2. Folkow B. Physiological aspects of primary hypertension. *Physiol Rev*. 1982; 62:347–504. [PubMed: 6461865]
3. Jackson WF. Ion channels and vascular tone. *Hypertension*. 2000; 35:173–178. [PubMed: 10642294]
4. Sonkusare S, Palade PT, Marsh JD, Telemaque S, Pesic A, Rusch NJ. Vascular calcium channels and high blood pressure: pathophysiology and therapeutic implications. *Vascul Pharmacol*. 2006; 44:131–142. [PubMed: 16427812]
5. Pesic A, Madden JA, Pesic M, Rusch NJ. High blood pressure upregulates arterial L-type Ca<sup>2+</sup> channels: is membrane depolarization the signal? *Circ Res*. 2004; 94:e97–e104. [PubMed: 15131006]
6. Amberg GC, Bonev AD, Rossow CF, Nelson MT, Santana LF. Modulation of the molecular composition of large conductance, Ca<sup>2+</sup> activated K<sup>+</sup> channels in vascular smooth muscle during hypertension. *J Clin Invest*. 2003; 112:717–724. [PubMed: 12952920]
7. Amberg GC, Santana LF. Downregulation of the BK channel beta1 subunit in genetic hypertension. *Circ Res*. 2003; 93:965–971. [PubMed: 14551242]
8. Firth AL, Remillard CV, Yuan JX. TRP channels in hypertension. *Biochim Biophys Acta*. 2007; 1772:895–906. [PubMed: 17399958]
9. Berridge MJ. Inositol trisphosphate and calcium signalling. *Nature*. 1993; 361:315–325. [PubMed: 8381210]
10. Narayanan D, Adebiyi A, Jaggar JH. Inositol trisphosphate receptors in smooth muscle cells. *Am J Physiol Heart Circ Physiol*. 2012; 302:H2190–H2210. [PubMed: 22447942]
11. Adebiyi A, Zhao G, Narayanan D, Thomas-Gatewood CM, Bannister JP, Jaggar JH. Isoform-Selective Physical Coupling of TRPC3 Channels to IP<sub>3</sub> Receptors in Smooth Muscle Cells Regulates Arterial Contractility. *Circ Res*. 2010; 106:1603–1612. [PubMed: 20378853]
12. Adebiyi A, Narayanan D, Jaggar JH. Caveolin-1 assembles type 1 inositol 1,4,5-trisphosphate receptors and canonical transient receptor potential 3 channels into a functional signaling complex in arterial smooth muscle cells. *J Biol Chem*. 2011; 286:4341–4348. [PubMed: 21098487]

13. Xi Q, Adebiyi A, Zhao G, Chapman KE, Waters CM, Hassid A, Jaggar JH. IP<sub>3</sub> constricts cerebral arteries via IP<sub>3</sub> receptor-mediated TRPC3 channel activation and independently of sarcoplasmic reticulum Ca<sup>2+</sup> release. *Circ Res*. 2008; 102:1118–1126. [PubMed: 18388325]
14. Zhao G, Adebiyi A, Blaskova E, Xi Q, Jaggar JH. Type 1 inositol 1,4,5-trisphosphate receptors mediate UTP-induced cation currents, Ca<sup>2+</sup> signals, and vasoconstriction in cerebral arteries. *Am J Physiol Cell Physiol*. 2008; 295:C1376–C1384. [PubMed: 18799650]
15. Bannister JP, Bulley S, Narayanan D, Thomas-Gatewood CM, Luzny P, Pachuau J, Jaggar JH. Transcriptional upregulation of α<sub>2</sub>δ-1 elevates arterial smooth muscle cell Ca<sub>v</sub>1.2 channel surface expression and cerebrovascular constriction in genetic hypertension. *Hypertension*. 2012 (In press).
16. Kiyonaka S, Kato K, Nishida M, Mio K, Numaga T, Sawaguchi Y, Yoshida T, Wakamori M, Mori E, Numata T, Ishii M, Takemoto H, Ojida A, Watanabe K, Uemura A, Kurose H, Morii T, Kobayashi T, Sato Y, Sato C, Hamachi I, Mori Y. Selective and direct inhibition of TRPC3 channels underlies biological activities of a pyrazole compound. *Proc Natl Acad Sci U S A*. 2009; 106:5400–5405. [PubMed: 19289841]
17. Tang J, Lin Y, Zhang Z, Tikunova S, Birnbaumer L, Zhu MX. Identification of common binding sites for calmodulin and inositol 1,4,5-trisphosphate receptors on the carboxyl termini of trp channels. *J Biol Chem*. 2001; 276:21303–21310. [PubMed: 11290752]
18. Yu Y, Fantozzi I, Remillard CV, Landsberg JW, Kunichika N, Platoshyn O, Tigno DD, Thistlethwaite PA, Rubin LJ, Yuan JX. Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. *Proc Natl Acad Sci U S A*. 2004; 101:13861–13866. [PubMed: 15358862]
19. Liu D, Scholze A, Zhu Z, Kreutz R, Wehland-von-Trebra M, Zidek W, Tepel M. Increased transient receptor potential channel TRPC3 expression in spontaneously hypertensive rats. *Am J Hypertens*. 2005; 18:1503–1507. [PubMed: 16280289]
20. Liu D, Scholze A, Zhu Z, Krueger K, Thilo F, Burkert A, Streffer K, Holz S, Harteneck C, Zidek W, Tepel M. Transient receptor potential channels in essential hypertension. *J Hypertens*. 2006; 24:1105–1114. [PubMed: 16685211]
21. Thilo F, Loddenkemper C, Berg E, Zidek W, Tepel M. Increased TRPC3 expression in vascular endothelium of patients with malignant hypertension. *Mod Pathol*. 2009; 22:426–430. [PubMed: 19136933]
22. Liu D, Yang D, He H, Chen X, Cao T, Feng X, Ma L, Luo Z, Wang L, Yan Z, Zhu Z, Tepel M. Increased transient receptor potential canonical type 3 channels in vasculature from hypertensive rats. *Hypertension*. 2009; 53:70–76. [PubMed: 19029480]
23. Chen X, Yang D, Ma S, He H, Luo Z, Feng X, Cao T, Ma L, Yan Z, Liu D, Tepel M, Zhu Z. Increased rhythmicity in hypertensive arterial smooth muscle is linked to transient receptor potential canonical channels. *J Cell Mol Med*. 2010; 14:2483–2494. [PubMed: 19725917]
24. Noorani MM, Noel RC, Marrelli SP. Upregulated TRPC3 and Downregulated TRPC1 Channel Expression during Hypertension is Associated with Increased Vascular Contractility in Rat. *Front Physiol*. 2011; 2:42. [PubMed: 21811471]
25. Xie L, Lin P, Xie H, Xu C. Effects of atorvastatin and losartan on monocrotaline-induced pulmonary artery remodeling in rats. *Clin Exp Hypertens*. 2010; 32:547–554. [PubMed: 21091363]
26. Zacikova L, Ondrias K, Kvetnansky R, Krizanova O. Identification of type 1 IP<sub>3</sub> receptors in the rat kidney and their modulation by immobilization stress. *Biochim Biophys Acta*. 2000; 1466:16–22. [PubMed: 10825427]
27. Piech A, Dessy C, Havaux X, Feron O, Balligand JL. Differential regulation of nitric oxide synthases and their allosteric regulators in heart and vessels of hypertensive rats. *Cardiovasc Res*. 2003; 57:456–467. [PubMed: 12566118]
28. Zhao YY, Liu Y, Stan RV, Fan L, Gu Y, Dalton N, Chu PH, Peterson K, Ross J Jr, Chien KR. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. *Proc Natl Acad Sci U S A*. 2002; 99:11375–11380. [PubMed: 12177436]
29. Beech DJ, Muraki K, Flemming R. Non-selective cationic channels of smooth muscle and the mammalian homologues of *Drosophila* TRP. *J Physiol*. 2004; 559:685–706. [PubMed: 15272031]



30. Pulina MV, Zulian A, Berra-Romani R, Beskina O, Mazzocco-Spezia A, Baryshnikov SG, Papparella I, Hamlyn JM, Blaustein MP, Golovina VA. Upregulation of Na<sup>+</sup> and Ca<sup>2+</sup> transporters in arterial smooth muscle from ouabain-induced hypertensive rats. *Am J Physiol Heart Circ Physiol*. 2010; 298:H263–H274. [PubMed: 19897708]
31. Zulian A, Baryshnikov SG, Linde CI, Hamlyn JM, Ferrari P, Golovina VA. Upregulation of Na<sup>+</sup>/Ca<sup>2+</sup> exchanger and TRPC6 contributes to abnormal Ca<sup>2+</sup> homeostasis in arterial smooth muscle cells from Milan hypertensive rats. *Am J Physiol Heart Circ Physiol*. 2010; 299:H624–H633. [PubMed: 20622104]
32. Jackson CL, Schwartz SM. Pharmacology of smooth muscle cell replication. *Hypertension*. 1992; 20:713–736. [PubMed: 1452288]
33. Fauconnier J, Lanner JT, Sultan A, Zhang SJ, Katz A, Bruton JD, Westerblad H. Insulin potentiates TRPC3-mediated cation currents in normal but not in insulin-resistant mouse cardiomyocytes. *Cardiovasc Res*. 2007; 73:376–385. [PubMed: 17156765]
34. Reading SA, Earley S, Waldron BJ, Welsh DG, Brayden JE. TRPC3 mediates pyrimidine receptor-induced depolarization of cerebral arteries. *Am J Physiol Heart Circ Physiol*. 2005; 288:H2055–H2061. [PubMed: 15604128]
35. Folkow B, Hallback M, Lundgren Y, Weiss L. Background of increased flow resistance and vascular reactivity in spontaneously hypertensive rats. *Acta Physiol Scand*. 1970; 80:93–106. [PubMed: 5475335]
36. Packer CS. Changes in arterial smooth muscle contractility, contractile proteins, and arterial wall structure in spontaneous hypertension. *Proc Soc Exp Biol Med*. 1994; 207:148–174. [PubMed: 7938046]
37. Aalkjaer C, Heagerty AM, Petersen KK, Swales JD, Mulvany MJ. Evidence for increased media thickness, increased neuronal amine uptake, and depressed excitation--contraction coupling in isolated resistance vessels from essential hypertensives. *Circ Res*. 1987; 61:181–186. [PubMed: 3621484]
38. Michel FS, Man RY, Vanhoutte PM. Increased spontaneous tone in renal arteries of spontaneously hypertensive rats. *Am J Physiol Heart Circ Physiol*. 2007; 293:H1673–H1681. [PubMed: 17557920]
39. Miller FJ Jr, Dellsperger KC, Gutterman DD. Myogenic constriction of human coronary arterioles. *Am J Physiol*. 1997; 273:H257–H264. [PubMed: 9249498]
40. Criscione L, Nellis P, Riniker B, Thomann H, Burdet R. Reactivity and sensitivity of mesenteric vascular beds and aortic rings of spontaneously hypertensive rats to endothelin: effects of calcium entry blockers. *Br J Pharmacol*. 1990; 100:31–36. [PubMed: 2196966]
41. Criscione L, Thomann H, Luu TD. Sensitivity and reactivity to endothelin-1 in mesenteric beds and aortic rings of 4-week-old spontaneously hypertensive rats. *Clin Exp Hypertens A*. 1992; 14:453–467. [PubMed: 1600640]

## Novelty and Significance

### 1. What is new?


- IP<sub>3</sub>R1 is located in close proximity to TRPC3 channels in mesenteric artery myocytes.
- Hypertension is associated with an increase in molecular localization of IP<sub>3</sub>R1 to TRPC3 channels.
- Enhanced physical and functional interaction between IP<sub>3</sub>R1 and TRPC3 channels induces vasoconstriction in hypertension

### 2. What is relevant?

- Smooth muscle cells regulate arterial diameter and thus, control blood flow.
- Vascular diseases, including hypertension, are associated with changes in vascular smooth muscle cell contractility that modifies blood flow and can lead to organ damage.
- Identifying mechanisms that elevate myocyte contractility in hypertension is important to develop new therapies for vascular diseases.


### Summary

Enhanced physical coupling between type 1 IP<sub>3</sub> receptors and TRPC3 channels in smooth muscle cells stimulates vasoconstriction during hypertension.




**Figure 1. IP<sub>3</sub>R1, TRPC3 and cav-1 are located in a macromolecular complex in rat mesenteric arteries**

Monoclonal mouse anti-IP<sub>3</sub>R1 antibody co-immunoprecipitated IP<sub>3</sub>R1 (~270 kDa), TRPC3 (~90 kDa), and cav-1 (~22 kDa). Lysate supernatant (~40 µg protein) was used as the input control and mouse IgG as the negative control. Arteries pooled from ~8 rats were used in this experiment.




**Figure 2. Hypertension is associated with an elevation in TRPC3, but not TRPC1, TRPC6, IP<sub>3</sub>R1 or cav-1, protein in arteries**

**A–E**, Western blots illustrating that TRPC3, but not TRPC1, TRPC6, IP<sub>3</sub>R1 or cav-1 protein, is higher in mesenteric arteries of hypertensive (13 week old) SHR than age-matched WKY rats. **F**, Western blot of TRPC3 in 6 week old pre-hypertensive SHR and age-matched WKY rat arteries. **G**, mean data. N=4–5; \* $P < 0.05$ .




**Figure 3. Plasma membrane-localized TRPC3 channel protein is higher in hypertensive SHR than WKY rat arteries**

**A**, Western blot and **B**, mean data (n=4) illustrating cellular distribution of TRPC3 in SHR and WKY rat arteries. **C**, mean data indicating that surface TRPC3 channel protein is higher in hypertensive SHR than WKY arteries (n=4). Protein samples were run on the same gel, but lanes were not contiguous. \* $P < 0.05$




**Figure 4. Hypertension is associated with an elevation in spatial localization of IP<sub>3</sub>R1 and TRPC3 channels in mesenteric artery myocytes**

**A**, Exemplar images illustrating immunofluorescence and N-FRET for IP<sub>3</sub>R1 and TRPC3 channels in hypertensive SHR and WKY rat isolated myocytes. Shown are fluorescent images generated by Alexa 488- and 546-conjugated antibodies, pixel overlay, and N-FRET for the same cells. **B**, mean N-FRET data for IP<sub>3</sub>R1 and TRPC3 channels in 13 week old rat myocytes (untreated control: WKY, n=9; SHR, n=6, Bt-IP<sub>3</sub>, 10 nM; WKY, n=7; SHR, n=11, and ET-1, 10 nM; WKY, n=6; SHR, n=6). **C**, mean N-FRET data for IP<sub>3</sub>R1 and TRPC3 channels in 6 week old rat myocytes (untreated control: WKY, n=6; SHR, n=6) and ET-1 (10 nM; WKY, n=6; SHR, n=7). \**P*<0.05 versus WKY basal N-FRET; #*P*<0.05 versus SHR basal N-FRET; †*P*<0.05 versus WKY in the same condition. Scale bar, 10 μm.



**Figure 5.  $IP_3$ -induced  $I_{Cat}$  is larger in hypertensive SHR than WKY rat arterial myocytes**

**A**, Exemplar traces and **B**, mean data indicating that control  $I_{Cat}$  density is similar and  $IP_3$  (10  $\mu$ M)-induced  $I_{Cat}$  is larger in hypertensive SHR than WKY rat myocytes. Pyr3 (1  $\mu$ M) and CIRBP-TAT (10  $\mu$ M) inhibited  $IP_3$ -induced  $I_{Cat}$  in both WKY and hypertensive SHR myocytes. Control WKY, n=4; control SHR, n=5;  $IP_3$  WKY, n=6;  $IP_3$  SHR, n=6;  $IP_3$ +Pyr3 WKY, n=7;  $IP_3$ +Pyr3 SHR, n=6;  $IP_3$ +CIRBP-TAT WKY, n=5;  $IP_3$ +CIRBP-TAT SHR, n=5. \* $P$ <0.05, versus control; † $P$ <0.05 versus WKY; # $P$ <0.05 versus  $IP_3$ .



**Figure 6. ET-1-induced vasoconstriction is larger in hypertensive SHR arteries, independent of SR Ca<sup>2+</sup> release, and attenuated by 2-APB, Pyr3 and CIRBP-TAT**

**A**, ET-1 concentration-response in SHR (EC<sub>50</sub>, 3.05 nM, n=8) and WKY (EC<sub>50</sub>, 2.4 nM, n=6) arterial rings. **B**, mean data (SHR, n=6 for each; WKY, n=8 for each) in the absence and presence of thapsigargin (Thapsi; 100 nM). **C**, mean data illustrating that 2-APB (50 μM), Pyr3 (1 μM) and CIRBP-TAT (3 μM) more effectively inhibit ET-1 (10 nM)-induced constriction in SHR arteries (n=6–9) \**P*<0.05, versus WKY; #*P*<0.05 versus control.